RxDoctor Payments Data

Mukti Patel-Chamberlin, MD

Nephrology · Cincinnati, OHNPI 1396951448

Payments from drug & device makers

$4,021in general payments, 2019–2025

Across 85 payments — averaging $47.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$962
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$712
  • Otsuka America Pharmaceutical, Inc.$486
  • Bayer$339
  • Akebia Therapeutics Inc$318
  • Boehringer Ingelheim$304
  • plus $902 from 13 others

What the payments were for

  • Consulting fees$61515%
  • Speaking & faculty fees$40010%
  • Food & beverage$2,79469%
  • Education$2125%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,021 in reported general payments places this provider in the 70th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$192,924
Medicare patients
408
Services billed
1,651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin41$69,795
FarxigaDapagliflozin Propanediol57$57,410
VeltassaPatiromer Calcium Sorbitex14$23,678
LokelmaSodium Zirconium Cyclosilicate24$11,705
Sevelamer Carbonate33$5,104
Nifedipine ErNifedipine106$4,637
Potassium Citrate ErPotassium Citrate14$2,223
Cinacalcet Hcl16$2,206
Losartan Potassium254$1,891
Torsemide42$1,542
Calcium Acetate26$1,145
Carvedilol84$820
Midodrine Hcl15$765
Valsartan39$763
Hydralazine Hcl42$743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$304$69,79541 claims
AstraZenecaFarxiga, Lokelma$962$69,11581 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 450 nephrology providers in Ohio.

Other nephrology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →